ジェネリック医薬品の市場規模、シェア、動向分析レポートタイプ別（シンプルジェネリック、スペシャリティジェネリック、バイオシミラー）、投与経路別、製品別、用途別、流通チャネル別、地域別＆セグメント予測、2023-2030年

ジェネリック医薬品市場の成長と動向

Grand View Research, Inc.の新しい調査によると、世界のジェネリック医薬品市場は、2023年から2030年にかけてCAGR 8.3%で拡大し、6829億米ドル以上に達すると予測されています。

ジェネリック医薬品市場の成長は、製品特許の失効により、ジェネリック医薬品やバイオシミラーメーカーが市場に製品を投入する道が開かれたことが主な要因です。例えば、2020年7月、Teva Pharmaceutical Industries Ltd.は、武田薬品工業株式会社と、専門資産、複雑なジェネリック医薬品、その他のパイプラインの製造と商業化を目的とした合弁会社を設立しました。このジョイントベンチャーは、ジェネリック医薬品市場を牽引すると予想されています。

さらに、医薬品にかかる総医療費を削減するために、ジェネリック医薬品を促進する政府の取り組みが増加しており、主要製品の特許が失効しています。例えば、オーストラリア治療薬庁（TGA）は、市民の治療のために、安価で効率的、かつ高品質で利用しやすいジェネリック医薬品を提供することを目的としています。ジェネリック医薬品を支援するため、TGAはジェネリック医薬品の規制状況や償還負担の軽減を図り、メーカーとの国際協力による障壁の軽減など、ジェネリック医薬品の市場投入に向けた取り組みを行っています。このようなオーストラリア政府の取り組みは、市場に新たな道を開くものです。

米国では、毎年数百万人の米国人が治療にジェネリック医薬品を使用しているため、医療保険制度においてジェネリック医薬品が最もお得であることに変わりはなく、「患者保護および医療費負担適正化法」の導入など、最近の医療改革法の制定を考慮すると、ジェネリック医薬品の普及が期待できます。P.L. 111-148。この法律では、これらの新しい医療保険制度の一部として、処方箋薬の適用が政府によって義務付けられています。このような政策の導入は、ヘルスケアの質と効率を向上させ、市場の成長を促進する可能性があります。

感染症や非感染症の疾病負担の増加、糖尿病や高血圧などの慢性疾患にかかりやすい老年人口の増加などは、市場の成長にプラスの影響を与える可能性があります。発表された記事によると、2022年9月、世界中で毎年約1,790万人の一般市民が心血管疾患（CVD）に苦しんでいます。結核、糖尿病、心血管疾患、HIVなどの疾患は、主な死因の1つです。これらの疾患の発生率や有病率の増加は、市場を牽引すると予想されます。

ジェネリック医薬品市場レポートハイライト

• タイプ別では、2022年に低分子セグメントが91.2%の最大シェアを占め、高分子セグメントは最も速い速度で成長すると予想されます。バイオシミラーの承認と取り込みの増加は、高分子セグメントの成長を促進すると予想されます。
• 投与経路別では、バイオシミラー医薬品の承認が進んでいることから、注射剤が最も急速に成長しています。
• 用途別では、心血管疾患が2022年に18.27%のシェアを占め、市場を独占しました。これは、高い疾患負担と相まって、ジェネリックスタチンの処方率が最も高いためです。
• スペシャリティジェネリックは、投資の増加や製薬会社が付加価値の高い製品の開発に注力していることから、緩やかな成長が期待されます。2019年、米国FDAは110の複合型ジェネリック医薬品を承認しました。
• 流通チャネルに基づくと、2022年には小売薬局セグメントが市場空間を支配しています。世界中の小売薬局チェーンは、売上を向上させ、より多くの顧客を引き付けるために、先進的な技術に投資し、新しい取り組みを行っている.
• 2022年、北米がシェアの大半を占める。政府の積極的な取り組みと、医薬品に対する償還状況の進化が、継続的な成長を支えています。

目次

第1章 調査手法と範囲

• 市場セグメンテーション
• 調査手法
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国別の市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報一覧
• 一次情報のリスト
• 1次調査分析
  • 市場シナリオ
  • 主なKoL応答
• 目的
• 略語一覧

第2章 エグゼクティブサマリー

• 市場のスナップショット
• セグメントのスナップショット
• 競争力のあるスナップショット

第3章 市場変数、動向、範囲

• 浸透と成長の見通しのマッピング
• 規制状況
• SWOT分析、要因別（政治と法律、経済、技術）
• ポーターのファイブフォース分析
• ユーザー視点分析
• ジェネリック医薬品市場力学
  • 市場促進要因分析
    • 生物製剤と低分子の特許の満了
    • ANDA承認の増加とジェネリック製品の発売
    • ジェネリック医薬品の使用を促進するための政府の取り組み
    • 疾病負担の増加と高齢者人口の増加
  • 市場抑制要因分析
    • 価格圧力

第4章 ジェネリック医薬品市場-セグメント分析、タイプ別、2018年から2030年（10億米ドル）

• ジェネリック医薬品市場：タイプの変動分析
• シンプルジェネリック
• 特殊ジェネリック
• バイオシミラー

第5章 ジェネリック医薬品市場-セグメント分析、アプリケーション別、2018年から2030年（10億米ドル）

• ジェネリック医薬品市場：アプリケーションの変動分析
• 中枢神経系疾患
• 呼吸器疾患
• ホルモンと関連疾患
• 消化器疾患
• 心血管疾患
• 感染症
• がん
• 糖尿病
• その他

第6章 ジェネリック医薬品市場-セグメント分析、製品別、2018年から2030年（10億米ドル）

• ジェネリック医薬品市場：製品変動分析
• 低分子
• 高分子

第7章 ジェネリック医薬品市場-セグメント分析、投与経路別、2018年から2030年（10億米ドル）

• ジェネリック医薬品市場：投与経路の変動分析
• 経口
• 注射可能
• 吸入可能
• その他

第8章 ジェネリック医薬品市場-セグメント分析、流通チャネル別、2018年から2030年（10億米ドル）

• ジェネリック医薬品市場：流通チャネルの変動分析
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 ジェネリック医薬品市場-セグメント分析、地域別、2018年から2030年（10億米ドル）

• ジェネリック医薬品市場、地域別市場シェア、2022年および2030年
• 北米
  • SWOT分析
  • 米国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • カナダ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 欧州
  • SWOT分析：
  • ドイツ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 英国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • フランス
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • イタリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スペイン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • デンマーク
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スウェーデン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • ノルウェー
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• アジア太平洋地域
  • SWOT分析：
  • 日本
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 中国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • インド
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • オーストラリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組みと償還のシナリオ
  • タイ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組みと償還のシナリオ
  • 韓国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組みと償還のシナリオ
• ラテンアメリカ
  • SWOT分析：
  • ブラジル
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • メキシコ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アルゼンチン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 中東およびアフリカ（MEA）
  • SWOT分析：
  • 南アフリカ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • サウジアラビア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アラブ首長国連邦
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • クウェート
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ

第10章 ジェネリック医薬品市場-競合分析

• 主要な市場参入企業別最近の動向と影響分析
  • 新製品の発売
  • 合併と買収
  • ライセンシング契約
  • カンファレンスとキャンペーン
• 会社の分類
  • イノベーター
  • 市場のリーダー
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
• 公開会社
  • 主要企業の市場シェア分析、2022年
  • 企業の市況分析
  • ヒートマップ分析
  • 競合ダッシュボード分析
    • 市場の差別化要因
• 非公開会社
  • 主要新興企業一覧
  • 地域ネットワークマップ
• 企業プロファイル
  • Teva Pharmaceutical Industries Ltd
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Viatris Inc.)
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Sun Pharmaceutical Industries Ltd.
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • LUPIN
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Novartis AG
    • Company overview
    • Sandoz International GmbH
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Allergan
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • AstraZeneca
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Sawai Pharmaceutical Co., Ltd.
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Hikma Pharmaceuticals PLC
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Dr. Reddy's Laboratories Ltd.
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Cipla Inc.
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Sanofi
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Aurobindo Pharma
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives
  • Endo International plc
    • Company overview
    • Financial performance
    • Product benchmarking
    • Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviation
• Table 3 Regulatory framework
• Table 4 Patent expiry
• Table 5 First generic products
• Table 6 Healthcare expenses on pharmaceuticals
• Table 7 Complex generic approved by U.S.FDA (2019)
• Table 8 Prevalence of GERD
• Table 9 Estimated new cancer case statistics, 2022
• Table 10 Total Glaucoma Cases (2020)
• Table 11 First generic oral products approved in 2019
• Table 12 Leading market players anticipated to witness highest growth
• Table 13 List of key distributor
• Table 14 North America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 15 North America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 16 North America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 17 North America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 18 North America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 19 U.S. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 20 U.S. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 21 U.S. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 22 U.S. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 23 U.S. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 24 Canada Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 25 Canada Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 26 Canada Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 26 Canada Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 27 Canada Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 28 Europe Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 29 Europe Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 29 Europe Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 30 Europe Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 31 Europe Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 32 U.K. Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 33 U.K. Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 34 U.K. Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 35 U.K. Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 36 U.K. Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 37 Germany Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 38 Germany Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 39 Germany Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 40 Germany Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 41 Germany Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 42 Italy Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 43 Italy Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 44 Italy Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 45 Italy Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 46 Italy Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 47 France Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 48 France Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 49 France Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 50 France Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 51 France Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 52 Spain Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 53 Spain Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 54 Spain Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 55 Spain Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 56 Spain Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 57 Denmark Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 58 Denmark Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 59 Denmark Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 60 Denmark Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 61 Denmark Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 62 Sweden Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 63 Sweden Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 64 Sweden Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 65 Sweden Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 66 Sweden Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 67 Norway Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 68 Norway Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 69 Norway Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 70 Norway Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 71 Norway Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 72 Asia Pacific Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 73 Asia Pacific Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 74 Asia Pacific Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 75 Asia Pacific Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 76 Asia Pacific Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 77 Japan Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 78 Japan Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 79 Japan Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 80 Japan Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 81 Japan Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 82 China Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 83 China Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 84 China Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 85 China Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 86 China Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 87 India Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 88 India Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 89 India Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 90 India Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 91 India Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 92 Australia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 93 Australia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 94 Australia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 95 Australia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 96 Australia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 97 South Korea Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 98 South Korea Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 99 South Korea Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 100 South Korea Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 101 South Korea Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 102 Thailand Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 103 Thailand Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 104 Thailand Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 105 Thailand Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 106 Thailand Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 107 Latin America Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 108 Latin America Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 109 Latin America Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 110 Latin America Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 111 Latin America Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 112 Brazil Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 113 Brazil Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 114 Brazil Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 115 Brazil Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 116 Brazil Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 117 Mexico Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 118 Mexico Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 119 Mexico Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 120 Mexico Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 121 Mexico Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 122 Argentina Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 123 Argentina Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 124 Argentina Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 125 Argentina Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 126 Argentina Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 127 MEA Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 128 MEA Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 129 MEA Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 130 MEA Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 131 MEA Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 132 South Africa Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 133 South Africa Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 134 South Africa Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 135 South Africa Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 136 South Africa Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 137 Saudi Arabia Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 138 Saudi Arabia Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 139 Saudi Arabia Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 140 Saudi Arabia Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 141 Saudi Arabia Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 142 UAE Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 143 UAE Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 144 UAE Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 145 UAE Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 146 UAE Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 147 KUWAIT Generic pharmaceuticals Market, By Type, 2018 - 2030 (USD Billion)
• Table 148 KUWAIT Generic pharmaceuticals Market, By Application, 2018 - 2030 (USD Billion)
• Table 149 KUWAIT Generic pharmaceuticals Market, By Product, 2018 - 2030 (USD Billion)
• Table 150 KUWAIT Generic pharmaceuticals Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 151 KUWAIT Generic pharmaceuticals Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Generic Pharmaceuticals market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Commodity Flow Analysis
• Fig. 10 Generic Pharmaceuticals Market Snapshot
• Fig. 11 Penetration and growth prospect mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 User Perspective Analysis
• Fig. 15 Generic Pharmaceuticals Market Driver Impact
• Fig. 16 Disease burden of non-communicable diseases (in Million), in 2018
• Fig. 17 Generic Pharmaceuticals Market Restraint Impact
• Fig. 18 Generic Pharmaceuticals market: Type outlook and key takeaways
• Fig. 19 Generic Pharmaceuticals market: Type movement analysis
• Fig. 20 Simple generics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 21 Specialty generics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 22 Biosimilars Market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 23 Generic Pharmaceuticals market: Application outlook and key takeaways
• Fig. 24 Generic Pharmaceuticals market: Application movement analysis
• Fig. 25 Central nervous system disorders market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 26 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 27 Hormones and related diseases market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 28 Gastrointestinal diseases market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 29 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 30 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 31 Cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 32 Diabetes market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 34 Generic Pharmaceuticals market: Product outlook and key takeaways
• Fig. 35 Generic Pharmaceuticals market: Product movement analysis
• Fig. 36 Small molecule market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 37 Large molecule market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 38 Generic Pharmaceuticals Market: Route of Administration Outlook and Key Takeaways
• Fig. 39 Generic Pharmaceuticals market: Route of administration movement analysis
• Fig. 40 Oral market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 41 Injectable market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 42 Inhalable market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 44 Generic Pharmaceuticals Market: Distribution Channel Outlook and Key Takeaways
• Fig. 45 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
• Fig. 46 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 47 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 48 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 49 Regional marketplace: Key takeaways
• Fig. 50 Regional outlook, 2020 & 2030
• Fig. 51 North America
• Fig. 52 North America. market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 53 U.S.
• Fig. 54 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 55 Canada
• Fig. 56 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 57 Europe
• Fig. 58 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 59 U.K.
• Fig. 60 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 61 Germany
• Fig. 62 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 63 France
• Fig. 64 France market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 65 Spain
• Fig. 66 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 67 Italy
• Fig. 68 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 69 Denmark
• Fig. 70 Denmark market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 71 Sweden
• Fig. 72 Sweden market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 73 Norway
• Fig. 74 Norway market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 75 Asia-Pacific
• Fig. 76 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 77 Japan
• Fig. 78 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 79 China
• Fig. 80 China market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 81 India
• Fig. 82 India market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 83 Australia
• Fig. 84 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 85 South Korea
• Fig. 86 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 87 Thailand
• Fig. 88 Thailand market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 89 Latin America
• Fig. 90 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 91 Brazil
• Fig. 92 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 93 Mexico
• Fig. 94 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 95 Argentina
• Fig. 96 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 97 Middle East & Africa
• Fig. 98 MEA market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 99 South Africa
• Fig. 100 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 101 Saudi Arabia
• Fig. 102 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 103 UAE
• Fig. 104 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 105 Kuwait
• Fig. 106 Kuwait market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 107 Market position analysis
• Fig. 108 Profit margin
• Fig. 109 Heat map analysis
• Fig. 110 Market differentiators
• Fig. 111 Regional Network Map

Generic Pharmaceuticals Market Growth & Trends:

The global generic pharmaceuticals market is expected to reach over USD 682.9 billion expanding at a CAGR of 8.3% from 2023 to 2030, according to a new study by Grand View Research, Inc. The growth of the generic pharmaceuticals market is largely attributable to the expiry of product patents which clears the way for generic drugs and biosimilar manufacturers to launch products in the market. For instance, in July 2020, Teva Pharmaceutical Industries Ltd. entered into a joint venture with Takeda Pharmaceutical Company Limited aimed to manufacture and commercialize specialty assets, complex generic drugs, and other pipeline opportunities. This joint venture was anticipated to drive the generic pharmaceuticals market.

Furthermore, increasing government initiatives to promote generic drug products for reducing the overall healthcare expenditure on pharmaceuticals and the patent expiry of major products. For instance, the Therapeutic Goods Administration (TGA) Australia aims to offer affordable, efficient, high-quality, and accessible generic drugs to citizens for their treatment. In support of generic drugs, the TGA has been trying to reduce regulatory and reimbursement burdens such as changing the landscape of generic drugs and reducing barriers through international collaboration with manufacturers to launch their generic drugs in the market. Such initiatives of the Australian government open new avenues in the market.

In the U.S., every year millions of Americans use a generic drug for their treatment, hence, generic drugs remain the best bargain in the health care insurance programs, and given the recent enactment of healthcare reform legislation such as the introduction of the Patient Protection and Affordable Health Care Act. P.L. 111-148. Under this act, prescription drug coverage is mandated by the government as part of these new health insurance plans. The introduction of such policies may improve the quality and efficiency of healthcare, thereby, driving market growth.

The rising disease burden of infectious & non-infectious diseases coupled with the increasing geriatric population which is prone to chronic diseases such as diabetes, and hypertension, among others, may positively affect the market growth. According to an article published, in September 2022, around 17.9 million general population suffer from cardiovascular diseases (CVD) every year worldwide. Diseases including TB, diabetes, cardiovascular diseases, and HIV were among the major causes of death. The increasing incidence and prevalence of these diseases is expected to drive the market.

Generic Pharmaceuticals Market Report Highlights:

• The small molecule segment by type held the largest share of 91.2% in 2022 and the large molecule segment is expected to grow at the fastest rate. The increasing approval and uptake of biosimilars is expected to drive the growth of the large molecule segment.

• Based on the route of administration, the injectable segment is the fastest-growing segment due to the rising approval for biosimilar drugs.

• By application, cardiovascular diseases dominated the market with a share of 18.27% in 2022, owing to the highest prescription rate of generic statins coupled with a high disease burden.

• Specialty generics are expected to grow moderately due to increasing investments and the focus of pharmaceutical companies to develop value-added products. In 2019, the U.S. FDA approved 110 complex generics.

• Based on distribution channel, the retail pharmacy segment dominated the market space in 2022. Retail pharmacy chains across the world are investing in advanced technologies and undertaking new initiatives to improve sales and attract more customers.

• North America held the majority share in 2022. Favorable government initiatives coupled with an evolving reimbursement landscape for pharmaceutical products support continual growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market segmentation
  • 1.1.1 Estimates and Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
• 1.7 Global Market: CAGR Calculation
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 List of Primary Sources
• 1.11 Primary Research Analysis
  • 1.11.1 Market scenario
  • 1.11.2 Key KoL responses
• 1.12 Objectives
  • 1.12.1 Objective 1:
  • 1.12.2 Objective 2:
• 1.13 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Snapshoty

Chapter 3 Market Variables, Trends & Scope

• 3.1 Penetration and Growth Prospect Mapping
• 3.2 Regulatory Landscape
• 3.3 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• 3.4 Porter's Five Forces Analysis
• 3.5 User Perspective Analysis
• 3.6 Generic Pharmaceuticals Market Dynamics
  • 3.6.1 Market Driver Analysis
    • 3.6.1.1 Patent expiry of biologics and small molecules
    • 3.6.1.2 Increasing ANDA approval and Generic Product Launches
    • 3.6.1.3 Government initiatives to promote usage of generics
    • 3.6.1.4 Increasing Disease Burden and Rising Geriatric Population
  • 3.6.2 Market Restraint Analysis
    • 3.6.2.1 Pricing Pressures

Chapter 4 Generic Pharmaceuticals Market - Segment Analysis, By Type, 2018 - 2030 (USD Billion)

• 4.1 Generic Pharmaceuticals Market: Type Movement Analysis
• 4.2 Simple Generics
  • 4.2.1 Simple Generics Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 4.3 Specialty Generics
  • 4.3.1 Specialty Generics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.4 Biosimilars
  • 4.4.1 Biosimilars Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Generic Pharmaceuticals Market - Segment Analysis, By Application, 2018 - 2030 (USD Billion)

• 5.1 Generic Pharmaceuticals Market: Application Movement Analysis
• 5.2 Central Nervous System Disorders
  • 5.2.1 Central Nervous System Disorders Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.3 Respiratory Diseases
  • 5.3.1 Respiratory Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.4 Hormones and Related Diseases
  • 5.4.1 Hormones and Related Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.5 Gastrointestinal Diseases
  • 5.5.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.6 Cardiovascular Diseases
  • 5.6.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.7 Infectious Diseases
  • 5.7.1 Infectious Diseases Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.8 Cancer
  • 5.8.1 Cancer Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.9 Diabetes
  • 5.9.1 Diabetes Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 5.10 Others
  • 5.10.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 6 Generic Pharmaceuticals Market - Segment Analysis, By Product, 2018 - 2030 (USD Billion)

• 6.1 Generic Pharmaceuticals Market: Product Movement Analysis
• 6.2 Small Molecule
  • 6.2.1 Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.3 Large Molecule
  • 6.3.1 Large molecule Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Generic Pharmaceuticals Market - Segment Analysis, By Route of Administration, 2018 - 2030 (USD Billion)

• 7.1 Generic Pharmaceuticals Market: Route of Administration Movement Analysis
• 7.2 Oral
  • 7.2.1 Oral Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 7.3 Injectable
  • 7.3.1 Injectable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 7.4 Inhalable
  • 7.4.1 Inhalable Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 7.5 Others
  • 7.5.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 8 Generic Pharmaceuticals Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Billion)

• 8.1 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
• 8.2 Hospital Pharmacy
  • 8.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 8.3 Retail Pharmacy
  • 8.3.1 Retail Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)
• 8.4 Online Pharmacy
  • 8.4.1 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Billion)

Chapter 9 Generic Pharmaceuticals Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)

• 9.1 Generic Pharmaceuticals Market, Market Share by Region, 2022 & 2030
• 9.2 North America
  • 9.2.1 SWOT Analysis
    • 9.2.1.1 North America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.2 U.S.
    • 9.2.2.1 Key Country Dynamics
    • 9.2.2.2 Target Disease Prevalence
    • 9.2.2.3 Competitive Scenario
    • 9.2.2.4 Regulatory Framework
    • 9.2.2.5 Reimbursement Scenario
    • 9.2.2.6 U.S. Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.3 Canada
    • 9.2.3.1 Key Country Dynamics
    • 9.2.3.2 Target Disease Prevalence
    • 9.2.3.3 Competitive Scenario
    • 9.2.3.4 Regulatory Framework
    • 9.2.3.5 Reimbursement Scenario
    • 9.2.3.6 Canada Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.2 Europe
  • 9.2.1 SWOT Analysis:
    • 9.2.1.1 Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.2 Germany
    • 9.2.2.1 Key Country Dynamics
    • 9.2.2.2 Target Disease Prevalence
    • 9.2.2.3 Competitive Scenario
    • 9.2.2.4 Regulatory Framework
    • 9.2.2.5 Reimbursement Scenario
    • 9.2.2.6 Germany Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.3 U.K.
    • 9.2.3.1 Key Country Dynamics
    • 9.2.3.2 Target Disease Prevalence
    • 9.2.3.3 Competitive Scenario
    • 9.2.3.4 Regulatory Framework
    • 9.2.3.5 Reimbursement Scenario
    • 9.2.3.6 UK Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.4 France
    • 9.2.4.1 Key Country Dynamics
    • 9.2.4.2 Target Disease Prevalence
    • 9.2.4.3 Competitive Scenario
    • 9.2.4.4 Regulatory Framework
    • 9.2.4.5 Reimbursement Scenario
    • 9.2.4.6 France Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.5 Italy
    • 9.2.5.1 Key Country Dynamics
    • 9.2.5.2 Target Disease Prevalence
    • 9.2.5.3 Competitive Scenario
    • 9.2.5.4 Regulatory Framework
    • 9.2.5.5 Reimbursement Scenario
    • 9.2.5.6 Italy Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.6 Spain
    • 9.2.6.1 Key Country Dynamics
    • 9.2.6.2 Target Disease Prevalence
    • 9.2.6.3 Competitive Scenario
    • 9.2.6.4 Regulatory Framework
    • 9.2.6.5 Reimbursement Scenario
    • 9.2.6.6 Spain Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.7 Denmark
    • 9.2.7.1 Key Country Dynamics
    • 9.2.7.2 Target Disease Prevalence
    • 9.2.7.3 Competitive Scenario
    • 9.2.7.4 Regulatory Framework
    • 9.2.7.5 Reimbursement Scenario
    • 9.2.7.6 Denmark Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.8 Sweden
    • 9.2.8.1 Key Country Dynamics
    • 9.2.8.2 Target Disease Prevalence
    • 9.2.8.3 Competitive Scenario
    • 9.2.8.4 Regulatory Framework
    • 9.2.8.5 Reimbursement Scenario
    • 9.2.8.6 Sweden Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.2.9 Norway
    • 9.2.9.1 Key Country Dynamics
    • 9.2.9.2 Target Disease Prevalence
    • 9.2.9.3 Competitive Scenario
    • 9.2.9.4 Regulatory Framework
    • 9.2.9.5 Reimbursement Scenario
    • 9.2.9.6 Norway Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.2.9.7 Rest of Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.3 Asia Pacific
  • 9.3.1 SWOT Analysis:
    • 9.3.1.1 Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.2 Japan
    • 9.3.2.1 Key Country Dynamics
    • 9.3.2.2 Target Disease Prevalence
    • 9.3.2.3 Competitive Scenario
    • 9.3.2.4 Regulatory Framework
    • 9.3.2.5 Reimbursement Scenario
    • 9.3.2.6 Japan Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.3 China
    • 9.3.3.1 Key Country Dynamics
    • 9.3.3.2 Target Disease Prevalence
    • 9.3.3.3 Competitive Scenario
    • 9.3.3.4 Regulatory Framework
    • 9.3.3.5 Reimbursement Scenario
    • 9.3.3.6 China Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.4 India
    • 9.3.4.1 Key Country Dynamics
    • 9.3.4.2 Target Disease Prevalence
    • 9.3.4.3 Competitive Scenario
    • 9.3.4.4 Regulatory Framework
    • 9.3.4.5 Reimbursement Scenario
    • 9.3.4.6 India Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.5 Australia
    • 9.3.5.1 Key Country Dynamics
    • 9.3.5.2 Target Disease Prevalence
    • 9.3.5.3 Competitive Scenario
    • 9.3.5.4 Regulatory Framework & Reimbursement Scenario
    • 9.3.5.5 Australia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.6 Thailand
    • 9.3.6.1 Key Country Dynamics
    • 9.3.6.2 Target Disease Prevalence
    • 9.3.6.3 Competitive Scenario
    • 9.3.6.4 Regulatory Framework & Reimbursement Scenario
    • 9.3.6.5 Thailand Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3.7 South Korea
    • 9.3.7.1 Key Country Dynamics
    • 9.3.7.2 Target Disease Prevalence
    • 9.3.7.3 Competitive Scenario
    • 9.3.7.4 Regulatory Framework & Reimbursement Scenario
    • 9.3.7.5 South Korea Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.3.7.6 Rest of Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.4 Latin America
  • 9.4.1 SWOT Analysis:
    • 9.4.1.1 Latin America Generic Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.4.2 Brazil
    • 9.4.2.1 Key Country Dynamics
    • 9.4.2.2 Target Disease Prevalence
    • 9.4.2.3 Competitive Scenario
    • 9.4.2.4 Regulatory Framework
    • 9.4.2.5 Reimbursement Scenario
    • 9.4.2.6 Brazil Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.3 Mexico
    • 9.4.3.1 Key Country Dynamics
    • 9.4.3.2 Target Disease Prevalence
    • 9.4.3.3 Competitive Scenario
    • 9.4.3.4 Regulatory Framework
    • 9.4.3.5 Reimbursement Scenario
    • 9.4.3.6 Mexico Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.4 Argentina
    • 9.4.4.1 Key Country Dynamics
    • 9.4.4.2 Target Disease Prevalence
    • 9.4.4.3 Competitive Scenario
    • 9.4.4.4 Regulatory Framework
    • 9.4.4.5 Reimbursement Scenario
    • 9.4.4.6 Argentina Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.4.7 Rest of Latin America Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.5 Middle East & Africa (MEA)
  • 9.5.1 SWOT Analysis:
    • 9.5.1.1 Middle East & Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.2 South Africa
    • 9.5.2.1 Key Country Dynamics
    • 9.5.2.2 Target Disease Prevalence
    • 9.5.2.3 Competitive Scenario
    • 9.5.2.4 Regulatory Framework
    • 9.5.2.5 Reimbursement Scenario
    • 9.5.2.6 South Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.3 Saudi Arabia
    • 9.5.3.1 Key Country Dynamics
    • 9.5.3.2 Target Disease Prevalence
    • 9.5.3.3 Competitive Scenario
    • 9.5.3.4 Regulatory Framework
    • 9.5.3.5 Reimbursement Scenario
    • 9.5.3.6 Saudi Arabia Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.4 UAE
    • 9.5.4.1 Key Country Dynamics
    • 9.5.4.2 Target Disease Prevalence
    • 9.5.4.3 Competitive Scenario
    • 9.5.4.4 Regulatory Framework
    • 9.5.4.5 Reimbursement Scenario
    • 9.5.4.6 UAE Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5.5 Kuwait
    • 9.5.5.1 Key Country Dynamics
    • 9.5.5.2 Target Disease Prevalence
    • 9.5.5.3 Competitive Scenario
    • 9.5.5.4 Regulatory Framework
    • 9.5.5.5 Reimbursement Scenario
    • 9.5.5.6 Kuwait Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.5.7 Rest of MEA Generic Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10 Generic Pharmaceuticals Market - Competitive Analysis

• 10.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 10.1.1 New Product Launch
  • 10.1.2 Merger and Acquisition
  • 10.1.3 Licensing Agreements
  • 10.1.4 Conferences and Campaigns
• 10.2 Company Categorization
  • 10.2.1 Innovators
  • 10.2.2 Market Leaders
• 10.3 Vendor Landscape
  • 10.3.1 List of key distributors and channel partners
  • 10.3.2 Key customers
• 10.4 Public Companies
  • 10.4.1 Key company market share analysis, 2022
  • 10.4.2 Company market position analysis
  • 10.4.3 Heat map analysis
  • 10.4.4 Competitive Dashboard Analysis
    • 10.4.4.1 Market Differentiators
• 10.5 Private Companies
  • 10.5.1 List of key emerging companies
  • 10.5.2 Regional Network Map
• 10.6 Company Profile
  • 10.6.1 Teva Pharmaceutical Industries Ltd
    • 10.6.1.1 Company overview
    • 10.6.1.2 Financial performance
    • 10.6.1.3 Product benchmarking
    • 10.6.1.4 Strategic initiatives
  • 10.6.2 Viatris Inc.)
    • 10.6.2.1 Company overview
    • 10.6.2.2 Financial performance
    • 10.6.2.3 Product benchmarking
    • 10.6.2.4 Strategic initiatives
  • 10.6.3 Sun Pharmaceutical Industries Ltd.
    • 10.6.3.1 Company overview
    • 10.6.3.2 Financial performance
    • 10.6.3.3 Product benchmarking
    • 10.6.3.4 Strategic initiatives
  • 10.6.4 LUPIN
    • 10.6.4.1 Company overview
    • 10.6.4.2 Financial performance
    • 10.6.4.3 Product benchmarking
    • 10.6.4.4 Strategic initiatives
  • 10.6.5 Novartis AG
    • 10.6.5.1 Company overview
    • 10.6.5.2 Sandoz International GmbH
    • 10.6.5.3 Financial performance
    • 10.6.5.4 Product benchmarking
    • 10.6.5.5 Strategic initiatives
  • 10.6.6 Allergan
    • 10.6.6.1 Company overview
    • 10.6.6.2 Financial performance
    • 10.6.6.3 Product benchmarking
    • 10.6.6.4 Strategic initiatives
  • 10.6.7 AstraZeneca
    • 10.6.7.1 Company overview
    • 10.6.7.2 Financial performance
    • 10.6.7.3 Product benchmarking
    • 10.6.7.4 Strategic initiatives
  • 10.6.8 Sawai Pharmaceutical Co., Ltd.
    • 10.6.8.1 Company overview
    • 10.6.8.2 Financial performance
    • 10.6.8.3 Product benchmarking
    • 10.6.8.4 Strategic initiatives
  • 10.6.9 Hikma Pharmaceuticals PLC
    • 10.6.9.1 Company overview
    • 10.6.9.2 Financial performance
    • 10.6.9.3 Product benchmarking
    • 10.6.9.4 Strategic initiatives
  • 10.6.10 Dr. Reddy's Laboratories Ltd.
    • 10.6.10.1 Company overview
    • 10.6.10.2 Financial performance
    • 10.6.10.3 Product benchmarking
    • 10.6.10.4 Strategic initiatives
  • 10.6.11 Cipla Inc.
    • 10.6.11.1 Company overview
    • 10.6.11.2 Financial performance
    • 10.6.11.3 Product benchmarking
    • 10.6.11.4 Strategic initiatives
  • 10.6.12 Sanofi
    • 10.6.12.1 Company overview
    • 10.6.12.2 Financial performance
    • 10.6.12.3 Product benchmarking
    • 10.6.12.4 Strategic initiatives
  • 10.6.13 Aurobindo Pharma
    • 10.6.13.1 Company overview
    • 10.6.13.2 Financial performance
    • 10.6.13.3 Product benchmarking
    • 10.6.13.4 Strategic initiatives
  • 10.6.14 Endo International plc
    • 10.6.14.1 Company overview
    • 10.6.14.2 Financial performance
    • 10.6.14.3 Product benchmarking
    • 10.6.14.4 Strategic initiatives